Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRXNASDAQ:FOLDNASDAQ:LGNDNASDAQ:RGLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$10.59+1.9%$8.38$5.92▼$11.11$2.22B1.083.03 million shs3.61 million shsFOLDAmicus Therapeutics$6.22-0.6%$7.11$5.81▼$12.65$1.92B0.642.84 million shs2.82 million shsLGNDLigand Pharmaceuticals$101.60+0.3%$105.46$77.43▼$129.90$1.96B0.87116,393 shs107,116 shsRGLSRegulus Therapeutics$7.89-0.3%$4.06$0.83▼$8.20$546.26M0.49902,748 shs1.81 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals0.00%+3.42%+28.83%+14.98%+59.01%FOLDAmicus Therapeutics0.00%-3.27%-13.61%-32.32%-36.01%LGNDLigand Pharmaceuticals0.00%-2.81%-6.40%-15.73%+16.41%RGLSRegulus Therapeutics0.00%+0.25%+181.79%+502.29%+310.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCRXBioCryst Pharmaceuticals4.6122 of 5 stars4.43.00.04.24.01.70.6FOLDAmicus Therapeutics3.8857 of 5 stars3.41.00.04.33.10.01.9LGNDLigand Pharmaceuticals4.332 of 5 stars3.50.00.04.42.93.31.9RGLSRegulus Therapeutics1.1696 of 5 stars2.13.00.00.02.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.89Moderate Buy$16.5656.33% UpsideFOLDAmicus Therapeutics 2.70Moderate Buy$16.22160.81% UpsideLGNDLigand Pharmaceuticals 3.00Buy$146.1443.84% UpsideRGLSRegulus Therapeutics 2.29Hold$8.507.73% UpsideCurrent Analyst Ratings BreakdownLatest RGLS, BCRX, LGND, and FOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/7/2025BCRXBioCryst PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $11.005/6/2025BCRXBioCryst PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $17.005/6/2025BCRXBioCryst PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/2/2025FOLDAmicus TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.005/2/2025FOLDAmicus TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.005/1/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$9.004/30/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2025RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$503.49M4.40N/AN/A($2.22) per share-4.77FOLDAmicus Therapeutics$543.14M3.53N/AN/A$0.63 per share9.87LGNDLigand Pharmaceuticals$181.49M10.80$4.17 per share24.39$40.39 per share2.52RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals-$226.54M-$0.26N/AN/AN/A-30.01%N/A-24.06%8/4/2025 (Estimated)FOLDAmicus Therapeutics-$151.58M-$0.09N/A14.471.51-10.62%12.44%2.60%N/ALGNDLigand Pharmaceuticals$52.15M-$7.1240.4827.39N/A29.68%4.95%4.39%8/5/2025 (Estimated)RGLSRegulus Therapeutics-$30.04M-$0.73N/AN/AN/AN/A-53.07%-48.58%N/ALatest RGLS, BCRX, LGND, and FOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/8/2025Q1 2025RGLSRegulus Therapeutics-$0.29-$0.15+$0.14-$0.15N/AN/A3/20/2025Q4 2024RGLSRegulus Therapeutics-$0.20-$0.20N/A-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A2.782.73FOLDAmicus Therapeutics2.013.392.42LGNDLigand PharmaceuticalsN/A12.4911.81RGLSRegulus TherapeuticsN/A14.1514.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%FOLDAmicus TherapeuticsN/ALGNDLigand Pharmaceuticals91.28%RGLSRegulus Therapeutics92.38%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals4.80%FOLDAmicus Therapeutics2.20%LGNDLigand Pharmaceuticals5.90%RGLSRegulus Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530209.25 million197.19 millionOptionableFOLDAmicus Therapeutics480307.93 million292.23 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.78 millionOptionableRGLSRegulus Therapeutics3069.23 million62.65 millionOptionableRGLS, BCRX, LGND, and FOLD HeadlinesRecent News About These CompaniesVelan Capital Investment Management LP Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS)May 22 at 6:01 AM | marketbeat.comPrice T Rowe Associates Inc. MD Has $47,000 Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)May 21, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Earns Sell Rating from Analysts at StockNews.comMay 20, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at StockNews.comMay 19, 2025 | americanbankingnews.comLatham and Covington Advise on Novartis’s Acquisition of RegulusMay 16, 2025 | lawstreetmedia.comOctagon Capital Advisors LP Acquires 585,101 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)May 15, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.comMay 12, 2025 | marketbeat.comRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 9, 2025 | finanznachrichten.deRegulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 8, 2025 | prnewswire.comWhat is Leerink Partnrs' Estimate for RGLS Q1 Earnings?May 6, 2025 | marketbeat.comJPMorgan Chase & Co. Purchases 111,485 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)May 5, 2025 | marketbeat.comREGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLSMay 4, 2025 | businesswire.comNovartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion DealMay 4, 2025 | gurufocus.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Sees Large Decline in Short InterestMay 4, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Lowered to "Hold" Rating by Wells Fargo & CompanyMay 4, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Downgraded to "Hold" Rating by Leerink PartnrsMay 4, 2025 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by RA Capital Management L.P.May 3, 2025 | marketbeat.comRegulus Therapeutics (RGLS) Projected to Post Earnings on ThursdayMay 3, 2025 | marketbeat.comWells Fargo Downgrades Regulus Therapeutics (RGLS)May 2, 2025 | msn.comNovartis to buy Regulus Therapeutics for as much as $1.7 billionMay 2, 2025 | latimes.comRegulus Therapeutics (NASDAQ:RGLS) Shares Pass Above 200-Day Moving Average - Here's What HappenedMay 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGLS, BCRX, LGND, and FOLD Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$10.59 +0.20 (+1.92%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$10.56 -0.04 (-0.33%) As of 05/23/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Amicus Therapeutics NASDAQ:FOLD$6.22 -0.04 (-0.64%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$6.31 +0.09 (+1.43%) As of 05/23/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ligand Pharmaceuticals NASDAQ:LGND$101.60 +0.31 (+0.31%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$101.72 +0.12 (+0.12%) As of 05/23/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Regulus Therapeutics NASDAQ:RGLS$7.89 -0.02 (-0.25%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$7.90 +0.00 (+0.06%) As of 05/23/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Alphabet Stock Lags—But Waymo May Be Its Hidden Driver Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
